Wedbush raises Neurocrine Bio stock price target on acquisition By Investing.com

Neurocrine agreed to acquire Soleno Therapeutics for $2.9B ($53.00/share), a ~34% premium to Soleno's April 2 close, with the deal expected to close in ~90 days and be accretive to revenue and non-GAAP EPS starting in 2026. Wedbush raised its price target on NBIX to $166 (from $151) while Cantor Fitzgerald lifted its target to $195; the stock trades at $132.48 implying material upside. Wedbush assumes ~$900M of debt financing, and models Vykat U.S. revenue reaching $995M by fiscal 2030 with ~19% peak market share.

Analysis

Neurocrine’s Soleno deal is a classic mid-cap tuck-in that boosts near-term revenue visibility while shifting execution risk from greenfield launch to integration and payer negotiation. The material second-order benefit is operating leverage: applying Neurocrine’s established sales, reimbursement access, and manufacturing footprint could compress Soleno’s standalone launch SG&A by an estimated 20–40%, turning a long, cash-burning launch into a much higher margin contribution by 2026–2028.

Funding the acquisition largely with debt (~$900m) meaningfully raises financial leverage in the 12–36 month window; expect net debt/EBITDA to spike, constraining discretionary buybacks and increasing sensitivity to rate moves and credit spreads. That elevates short-term tail risk (rating pressure, higher interest expense) even as EPS accretion is plausible by 2026 — so the financing path is a trade-off between accelerated growth and balance-sheet optionality.

The street models U.S.-only uptake for Vykat; the larger, under-appreciated upside is staggered ex-U.S. launches and rare-disease center adoption, which could add 20–40% to peak revenue but with 2–5 year lag and higher rebate/price-pressure. Conversely, the most plausible downside is tougher-than-expected payer resistance on a rare-disease price point or unexpected manufacturing scale constraints that push meaningful revenue out past 2026, flipping near-term accretion into dilution.

Key near-term catalysts are the ~90-day close, updated FY26 guidance, and any commentary on financing/covenants; binary risks include regulatory/label narrowing, post-close supply interruptions, or a credit-rating action if leverage thresholds are breached.

Key Decisions for Investors

• Buy NBIX equity on a pullback below $125 — target 30–45% total return in 12–24 months (price target range $165–185). Rationale: accretive deal, reuse of commercial infrastructure; set tactical stop-loss at 15% to limit leverage-driven drawdowns.
• Buy NBIX Jan 19 2027 $160 calls (or equivalent LEAPs) sized so max premium = 2–4% portfolio risk. Risk/reward: asymmetric — if deals and guidance cement 2026 accretion, 2–3x+ upside vs premium loss if financing or execution disappoints within 12–18 months.
• Protective collar on NBIX for core long positions: buy 12-month 20% OTM puts and sell 12–18 month 30–40% OTM calls to finance protection. This hedges balance-sheet/leverage shock while preserving meaningful upside to analyst targets.
• Event-risk monitor: if post-close guidance is weak or credit spreads widen >150bps, consider trimming size or switching to a pair trade (long biotech names with strong balance sheets / short NBIX) to neutralize sector beta while retaining deal-specific downside exposure.